Marked response to icotinib in lung squamous cell carcinoma with EGFR wild-type

ABSTRACT

We present a case of a 72-year male with primary lung squamous cell carcinoma without an epidermal growth factor receptor [EGFR] gene mutation that exhibited a lasting efficacy to icotinib treatment. Originally, the patient was treated with GP regimen for 2 cycles, local lesion radiotherapy [DT46Gy/2Gy*23F], and TP regimen for 2 cycles, with efficacy evaluation as stable disease [SD]. The condition was stable for 10 months until the fifth lumbar metastasis was discovered by emission computed tomography [ECT] in July 2015, and the pulmonary metastasis increased. Icotinib was administered at 125 mg orally three times per day. Chest computed tomography [CT] scan showed the tumor was in partial response [PR] and the PR lasted for 27 months